Abstract 53P
Background
Breast cancer is the predominant malignancy in Indonesia, as per recent data from The Global Cancer Observatory (GLOBOCAN) 2020. Employing a multifaceted therapeutic approach has curbed breast cancer patient mortality. Radiotherapy's pivotal role in comprehensive breast cancer care underscores its significance. This study marks the inaugural effort to assess radiotherapy utilization rate (RUR) among Indonesian breast cancer patients.
Methods
Secondary data were gathered from breast cancer patients diagnosed within Indonesian radiotherapy centers during 2019-2021. The primary goal was a pre-pandemic evaluation of radiotherapy utilization. After rigorous data cleansing, involving duplicate elimination, meticulous analysis ensued. This unveiled actual RUR (aRUR) and optimal RUR (oRUR) for this cohort. Comparative RUR assessment with global counterparts complemented the analysis.
Results
This study encompassed 11,037 breast cancer patients from 34 Indonesian radiotherapy centers. Of these, 96.8% were female, with a minority (2.6%) being male. Notably, 60.38% were diagnosed at advanced stages (Stages 3 and 4), mirroring developing nation trends. 17 radiotherapy centers met the criteria for aRUR analysis, resulting in 26.2%. For oRUR, 9 centers were suitable, indicating 66.3% (50.7% - 78.2%). Consequently, unmet RUR needs in Indonesian breast cancer patients stood at 60.4% (48.3% - 66.4%). Data from Australia's Cancer Collaboration for Cancer Outcomes, Research & Evaluation (CCORE) 2013 exhibited a higher oRUR of 83.5% (82.5% - 84.6%), attributed to significant stage distribution differences.
Conclusions
The underutilization of radiotherapy for Indonesian breast cancer patients persists. A notable disparity between oRUR and aRUR remains. Given these outcomes, imperative next steps entail delving into underlying factors fueling this gap and devising targeted strategies to mitigate the concern.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract